Clinical efficacy and safety of J022X ST in the prevention of Recurrent Upper-Respiratory Tract Infections (RURTI) in children with a high risk of recurrence
Clinical efficacy and safety of J022X ST in the prevention of Recurrent Upper-Respiratory Tract Infections (RURTI) in children with a high risk of recurrence
CLEARI
Clinical efficacy and safety of J022X ST in the prevention of Recurrent Upper-Respiratory Tract Infections (RURTI) in children with a high risk of recurrence
Statut
Status :
Terminé
Type d'étude
Phase III
Age Min.
2
Ans
Age Max.
11
Ans
Genre
Tous
Aire thérapeutique :
Pneumologie
Maladie :
Infection respiratoire
Traitement :
Ribomunyl
Phase :
Phase III
Date de début de l'étude :
02 Septembre 2013
End date :
17 Octobre 2016
Identifiant de l'essai :
J0022X ST 302
Identifiant EudraCT/CTIS :
2013-001760-31
Identifiant CT.gov :
NCT01948856
Envoyer par email